Twitter LinkedIn
Return to Wellspring

Communicate

Cancer Immunotherapy Using Nanoparticles and the Generation of Functional Dendritic Cells

Details

Project TitleCancer Immunotherapy Using Nanoparticles and the Generation of Functional Dendritic Cells
Track Code2020
Short Description

The technology includes novel nanoparticles which have a mitochondrial targeting moiety and a photosensitizer configured to produce a reactive oxygen species when exposed to light of an appropriate wavelength, as well as a method of using these particles. Dysfunction of a host’s immune system is one of the major mechanisms by which tumors evade immune surveillance.  Tumors employ strategies to successfully evade the host immune system, and these strategies may target immune antitumor effector cells.  Dysfunction and apoptosis of these immune antitumor effector cells in the host creates an immune imbalance that cannot be corrected by immunotherapies aimed only at activation of anti-tumor immune response.  Reversal of existing immune dysfunction and normalization of lymphocyte homeostasis in patients with cancer may play an important role in future cancer immunotherapies.

Abstract

A therapeutic technology that combines the phototoxic and immune-stimulating ability of photodynamic therapy (PDT) with the widespread effectiveness of the immune system can be very promising to treat – for instance - metastatic breast cancer. Dr. Shanta Dhar and Donald Harn developed nanoparticles which have a mitochondrial targeting moiety and a photosensitizer configured to produce a reactive oxygen species when exposed to light of an appropriate wavelength. Cancer cells that have been exposed to nanoparticles and then activated using the photosensitizer undergo apoptosis and cause activation of dendritic cells, leading to the production of high levels of IFN-γ and tumor destruction. This technology is suitable for the treatment of cancer through increasing the immunogenicity of cancerous cells and may be especially relevant to metastatic cancers. Its activity has been successfully demonstrated using breast cancer cells. The invention induces IFN-γ production, which is more powerful than other non-specific stimulants such as IFN-α and interleukin-2. Because the mode of action is through the stimulation of the patient’s own immune system, this approach should be far less toxic than traditional cancer chemotherapies. Further dendritic cells can be activated ex vivo and IFN-γ produced in bulk quantities and, since the dendritic cells are produced ex vivo, culture conditions can be carefully controlled and cell quality checked before any administration of cells to a patient.  Thus, the technology provides for a therapeutic measure, but also for a platform for the commercial cell culture based production of IFN-γ.

References and Intellectual Property

 

 
Tagscancer, immunotherapy
 
Posted DateNov 14, 2017 11:51 AM

People

Name
Gennaro Gama

Files

File Name Description
2020 Dhar RW.doc None Download